(firstQuint)Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer.

 This is a phase III,Multi-center,prospective,randomized clinical trials.

 The objective compare the efficacy of bicalutamide with conventional chemotherapy (Treatment of Physician's Choice,TPC) in first-line treatment of AR positive metastatic triple negative breast cancer.

Primary endpoint is 16-week clinical benefit rate (CBR).

By centre randomized grouping bicalutamide (experimental Group) or TPC (Control Group).

.

 Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer@highlight

Compare the efficacy of bicalutamide with conventional chemotherapy (Treatment of Physician's Choice,TPC) in first-line treatment of AR positive metastatic triple negative breast